Global biopharmaceutical company to support the accelerated growth of comprehensive genomic and clinical data set for the advancement of precision treatment of multiple myeloma
Norwalk, CT, July 8, 2021 – The Multiple Myeloma Research Foundation (MMRF) today announced Sanofi as its first collaborative partner to support the groundbreaking MMRF CureCloud research initiative. Launched in July 2020, the MMRF CureCloud is a first-of-its-kind research study that collects genomic and clinical information from multiple myeloma patients through an at-home consent and testing process. This rich longitudinal database aims to speed the delivery of precision therapies and a cure for each and every multiple myeloma patient, consistent with the mission of the MMRF.
Every multiple myeloma patient who enrolls in the MMRF CureCloud is provided free access to myeloma specific genomic sequencing so that they can make more informed decisions with their physicians about the right treatment options to optimize outcomes. At the same time, the datasets from the MMRF CureCloud are accessible to researchers to better treat, improve outcomes, and ultimately lead to cures for multiple myeloma’s many subtypes. As the number of patients enrolled in the MMRF CureCloud reaches a critical mass, the entire myeloma community will be able to explore the database to find other participants who share similar characteristics to inform clinical decisions and advance precision medicine for every patient.
“The MMRF CureCloud is revolutionizing the way in which patients participate in research by breaking down barriers to critical information that puts the power of precision medicine in the hands of myeloma patients,” said Michael Andreini, President and Chief Executive Officer. “We are grateful to Sanofi for their support of this innovative program. Collaborative partnerships like this are helping to drive new discoveries as we pursue a cure for every myeloma patient.”
As a collaborative partner, Sanofi will have access to the MMRF CureCloud to potentially advance its scientific research in multiple myeloma. Sanofi will also serve on the MMRF CureCloud Advisory Committee and provide strategic and scientific guidance along with principal investigators, bioinformatics leaders, and patient advocates on the future direction of the program and data registry. This partnership marks the first of what will be several members of the multiple myeloma community working together to accelerate cures through the MMRF CureCloud. Through these partnerships, the MMRF will enroll and process new data that will yield a better understanding of how to treat each and every patient individually based on their multiple myeloma subtype.
“We are proud to be the first industry partner of the MMRF CureCloud,” said Zsuzsanna Devecseri, Head of Global Oncology Medical Affairs at Sanofi. “This innovative, real-world patient-centered registry is transformative in the way data are collected and has the potential to impact patient care. We look forward to seeing the impact it has for people living with this difficult-to-treat cancer.”
Learn more about how the MMRF CureCloud is ushering in a new era of healthcare here.
About the Multiple Myeloma Research Foundation (MMRF)
A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c)(3) nonprofit organization, the MMRF has created the business model around cancer—from data to analytics to the clinic. The MMRF identifies barriers and then finds the solutions to overcome them, bringing in the best partners and aligning incentives in the industry to drive better outcomes for patients. Since its inception, the organization has collected thousands of samples and tissues, opened nearly 100 trials, helped bring 15 FDA-approved therapies to market, and built CoMMpass, the single largest genomic dataset for any cancer. Today, the MMRF is building on its legacy in genomics and is expanding into immunotherapy, as the combination of these two fields will be critical to making precision medicine possible for all patients. The MMRF has raised more than $500 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.